C-C型基序趋化因子受体4(C-C motif chemokine receptor 4,CCR4)属于G蛋白偶联受体家族,是一种趋化因子受体,胸腺活化调节趋化因子(thymus activation regulates chemokines,TARC/CCL17)与巨噬细胞衍生的趋化因子(macrophage-derived chemokines,MDC/CCL22)是其高亲和力受体.CCR4在某些肿瘤细胞中高表达,可促进肿瘤的发生、发展、增殖和转移,与肿瘤的不良生物学行为密切相关.同时,CCR4可以通过调节性T细胞(regulatory T cell.Treg)导致肿瘤免疫逃逸.鉴于其在恶性肿瘤中的双重作用,其靶向治疗药物莫加珠单抗(mogamulizumab,mAb)在成人 T 细胞白血病/淋巴瘤(adult T cell leukemia/lymphoma,ATLL)以及皮肤 T细胞淋巴瘤(cutaneous T cell lymphomas,CTCLs)中的开发和临床应用取得了显著成效,但目前mAb在实体瘤中的应用还不明确,尚需进一步的实验研究和探索.由于CCR4在不同肿瘤中的表达机制和意义不同,以及其单克隆抗体在恶性肿瘤中的研究进展的差异,本研究就CCR4在不同肿瘤中的双重作用以及其靶向药物的研究进展进行综述.
The Role of CCR4 in Malignant Tumor and the Research Progress of Targeted Therapy
C-C motif chemokine receptor 4(CCR4),a chemokine receptor,belongs to the G protein-coupled receptor family.Thymus activation regulators chemokines(TARC/CCL17)and macrophage-derived chemokines(MDC/CCL22)are its high affinity receptors.The high expression of CCR4 in some tumor cells promotes the occurrence,growth,proliferation and metastasis of tumors,which is closely related to the bad biological behavior of tumors.At the same time,CCR4 can lead to tumor immune escape through regulatory T cell(Treg).In view of its dual functions in malignant tumors,the development and clinical application of its targeted therapeutic drug mogamulizumab(mAb)in adult T cell leukemia/lymphoma(ATLL)and cutaneous T cell lymphomas(CTCLs)have achieved remarkable success,but the application of mAb in solid tumors is still unclear,and further exper-imental research is needed.Because of the different expression mechanism and significance of CCR4 in different tumors and the different research progress of its monoclonal antibody in malignant tumors,this paper reviews the dual functions of CCR4 in different tumors and the research progress of its targeted drugs.
万方数据
维普
